New Delhi, April 27 (IANS) Researchers have found a new approach which holds great promise to treat a common form of Irritable Bowel Syndrome (IBS).
This approach which includes personalised ‘cocktails’ of antibiotics, probiotics and prebiotics was found to improve symptoms in almost all patients who were included in the study published in the journal European Society Of Clinical Microbiology And Infectious Diseases.
As per lead researcher Professor Maurizio Sanguinetti, “The research shows that about 10-30 per cent of individuals who experience acute gastroenteritis develop Post-infection IBS. Symptoms like diarrhoea, constipation, bloating and abdominal pain can last for months or even years after the initial infection.”
Post-infection IBS (PI-IBS) is a form of irritable bowel syndrome that occurs after gastroenteritis or food poisoning.
To investigate the potential of this approach, the researchers performed a study on 13 PI-IBS patients (8 males and 5 females; mean age, 31 years) who were treated with targeted gut-microbiota therapy.
Nine patients (69.2 per cent) had diarrhoea-dominant IBS (IBS-D), while four (30.8 per cent) had constipation-dominant IBS (IBS-C).
Bloating and stomach pain were reported in 69.2 per cent (9/13) and 76.9 per cent (10/13) of patients, respectively.
Based on their results, researchers then designed a personalised therapy for each patient with the goal of rebalancing their gut microbiota.
The therapies consisted of short courses of the antibiotics rifaximin (9/13, 69 per cent of patients) or paromomycin (4/13, 31 per cent) to reduce levels of potentially harmful bacteria, followed by prebiotics or postbiotics to improve the numbers of protective bacteria and contest with the harmful bacteria for space and resources.
Twelve weeks after starting treatment, 93 per cent of patients improved their symptoms, and 38.5 per cent attained overall remission, the study noted.
“A precision medicine approach, in which testing and careful analysis of the gut microbiota allows the development of personalised treatments holds great promise in the treatment of PI-IBS,” Sanguinetti said.
–IANS
shs/rad
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
